{"id":103267,"date":"2020-11-02T20:26:00","date_gmt":"2020-11-02T17:26:00","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/curevacs-covid-19-vaccine-shows-immune-response-in-phase-1-trial\/"},"modified":"2020-11-02T20:26:00","modified_gmt":"2020-11-02T17:26:00","slug":"curevacs-covid-19-vaccine-shows-immune-response-in-phase-1-trial","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/curevacs-covid-19-vaccine-shows-immune-response-in-phase-1-trial\/","title":{"rendered":"#\n  CureVac\u2019s COVID-19 vaccine shows immune response in Phase 1 trial"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3df38413c6d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #dd3333;color:#dd3333\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #dd3333;color:#dd3333\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3df38413c6d\" checked aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/buradabiliyorum.com\/en\/curevacs-covid-19-vaccine-shows-immune-response-in-phase-1-trial\/#The_biotech_firm_is_using_the_so-called_messenger_RNA_mRNA_approach_to_develop_a_vaccine\" >The biotech firm is using the so-called messenger RNA (mRNA) approach to develop a vaccine<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/buradabiliyorum.com\/en\/curevacs-covid-19-vaccine-shows-immune-response-in-phase-1-trial\/#CureVac_said_it_is_on_track_to_launch_the_final_stage_of_testing_after_its_COVID-19_vaccine_triggered_an_immune_response_in_the_Phase_1_trial\" >CureVac said it is on track to launch the final stage of testing, after its COVID-19 vaccine triggered an immune response in the Phase 1 trial.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/buradabiliyorum.com\/en\/curevacs-covid-19-vaccine-shows-immune-response-in-phase-1-trial\/#Lina_Saigol\" >Lina Saigol<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<p>&#8220;<strong>#<br \/>\n  CureVac\u2019s COVID-19 vaccine shows immune response in Phase 1 trial<br \/>\n<\/strong>&#8221;<\/p>\n<h2 class=\"article__subhead\" itemprop=\"alternativeHeadline\"><span class=\"ez-toc-section\" id=\"The_biotech_firm_is_using_the_so-called_messenger_RNA_mRNA_approach_to_develop_a_vaccine\"><\/span>\n  The biotech firm is using the so-called messenger RNA (mRNA) approach to develop a vaccine<br \/>\n<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><\/p>\n<div class=\"column column--full article__content\">\n<div id=\"js-article__body\" class=\"article__body article-wrap at16-col16 barrons-article-wrap\" itemprop=\"articleBody\" data-sbid=\"WP-MKTW-0000053188\">\n<div class=\"barrons-article-ad-wrapper\">\n<div data-track=\"barrons-article-ad-wrap\" class=\"barrons-article-ad sticky_item\">\n<div class=\"barrons-main-article-ad-target sticky_target body_ad\" aria-hidden=\"true\"><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div data-layout=\"inline\n              \" data-layout-mobile=\"\" class=\"\n        media-object\n        type-InsetMediaIllustration\n          inline\n  article__inset\n        article__inset--type-InsetMediaIllustration\n          article__inset--inline\n  \"><\/p>\n<figure class=\"\n        media-object-image\n        enlarge-image\n        renoImageFormat-\n        img-inline\n        article__inset__image\n      \" itemscope itemtype=\"http:\/\/schema.org\/ImageObject\"><\/p>\n<div style=\"padding-bottom:56.40625%;\" data-mobile-ratio=\"56.40625%\" data-layout-ratio=\"56.40625%\" data-subtype=\"\" class=\"image-container  responsive-media article__inset__image__image\">\n        <img decoding=\"async\" srcset=\"https:\/\/images.mktw.net\/im-253290?width=140&amp;size=1.7728531855955678 140w,\nhttps:\/\/images.mktw.net\/im-253290?width=540&amp;size=1.7728531855955678 540w,\nhttps:\/\/images.mktw.net\/im-253290?width=620&amp;size=1.7728531855955678 620w,\nhttps:\/\/images.mktw.net\/im-253290?width=700&amp;size=1.7728531855955678 700w,\nhttps:\/\/images.mktw.net\/im-253290?width=860&amp;size=1.7728531855955678 860w,\nhttps:\/\/images.mktw.net\/im-253290?width=1260&amp;size=1.7728531855955678 1260w\" sizes=\"(max-width: 140px) 100px,\n(max-width: 540px) 500px,\n(max-width: 620px) 580px,\n(max-width: 700px) 660px,\n(max-width: 860px) 820px,\n1260px\" src=\"https:\/\/images.mktw.net\/im-253290?width=620&amp;size=1.7728531855955678\" data-enlarge=\"https:\/\/images.mktw.net\/im-253290?width=1260&amp;size=1.7728531855955678\" alt=\"\" title=\"CureVac said it is on track to launch the final stage of testing, after its...\"><\/div><figcaption class=\"wsj-article-caption article__inset__image__caption\" itemprop=\"caption\">\n<h4 class=\"wsj-article-caption-content\"><span class=\"ez-toc-section\" id=\"CureVac_said_it_is_on_track_to_launch_the_final_stage_of_testing_after_its_COVID-19_vaccine_triggered_an_immune_response_in_the_Phase_1_trial\"><\/span>CureVac said it is on track to launch the final stage of testing, after its COVID-19 vaccine triggered an immune response in the Phase 1 trial.<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p>      <span class=\"wsj-article-credit article__inset__image__caption__credit\" itemprop=\"creator\"><br \/>\n            thomas kienzle\/Agence France-Presse\/Getty Images<br \/>\n          <\/span><br \/>\n  <\/figcaption><\/figure>\n<\/div>\n<p>       Shares in CureVac jumped higher on Monday, after the German biotech company said its experimental COVID-19 vaccine triggered a good immune response in humans in a Phase 1 clinical study, placing it on track to launch the final stage of testing before the end of 2020.<\/p>\n<p> T\u00fcbingen-based CureVac<br \/>\n        CVAC,<br \/>\n        <bg-quote field=\"percentchange\" format=\"0,000.00%\" channel=\"\/zigman2\/quotes\/219999729\/composite\" class=\"negative\">-2.09%<\/bg-quote><br \/>\n       said in a <a rel=\"nofollow noopener noreferrer\" target=\"_blank\" href=\"https:\/\/www.curevac.com\/en\/2020\/11\/02\/curevac-reports-positive-interim-phase-1-data-for-its-covid-19-vaccine-candidate-cvncov\/\" class=\"icon none\">statement<\/a> that the strongest dose of the vaccine, known as CVnCoV, produced an immune response in volunteers comparable with patients who had recovered from being hospitalized with a case of COVID-19.<\/p>\n<div class=\"paywall\">\n       The clinical data haven\u2019t yet been published in peer-review format.<\/p>\n<p>\u201cWe are very encouraged by the interim Phase 1 data,\u201d said Franz-Werner Haas, chief executive of CureVac. \u201cFollowing further data readouts and discussion with regulatory authorities, we remain fully committed and on track to initiate a pivotal Phase 2b\/3 trial before the end of 2020.\u201d <\/p>\n<p>CureVac\u2019s U.S.-listed shares, which trade on Nasdaq, rose 2.93% higher on Monday. <\/p>\n<p>CureVac is using the so-called messenger RNA (mRNA) <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/download-scripts-themes-apps\/\" data-internallinksmanager029f6b8e52c=\"9\" title=\"Download Scripts &amp; Themes &amp; Apps\" target=\"_blank\" rel=\"noopener\">app<\/a>roach to develop a vaccine for COVID-19, which instruct cells to create proteins to generate an immune response protecting against a virus. <\/p>\n<p>No RNA vaccine has yet been approved by regulators. <\/p>\n<p><strong>Read:<\/strong> COVID-19 immunity may only last a few months after infection, study indicates <\/p>\n<p>Several other companies are also using this approach to develop a vaccine, including U.S. companies Moderna as well as BioNTech<br \/>\n        BNTX,<br \/>\n        <bg-quote field=\"percentchange\" format=\"0,000.00%\" channel=\"\/zigman2\/quotes\/214419716\/composite\" class=\"negative\">-1.45%<\/bg-quote><br \/>\n       and its partner Pfizer<br \/>\n        PFE,<br \/>\n        <bg-quote field=\"percentchange\" format=\"0,000.00%\" channel=\"\/zigman2\/quotes\/202877789\/composite\" class=\"positive\">+1.28%<\/bg-quote><span>,<\/span><br \/>\n       which started mass testing on humans in late July.<\/p>\n<div id=\"cx-membership-tile\"><\/div>\n<p><strong>Read:<\/strong> Moderna\u2019s stock is up as it says it is \u2018actively preparing\u2019 for launch of COVID-19 vaccine <\/p>\n<p>Together, Pfizer and BioNTech say that they have the capacity to manufacture 100 million doses of their vaccine this year, and at least 1.3 billion doses in 2021. <\/p>\n<p><strong>Read:<\/strong> Pfizer and BioNTech says European Medicines Agency to review data from COVID-19 vaccine trial on rolling basis  <\/p>\n<p>CureVac said the Phase 1 trial data was <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/general\/\" data-internallinksmanager029f6b8e52c=\"3\" title=\"General\" target=\"_blank\" rel=\"noopener\">general<\/a>ly well tolerated across all five tested doses \u2014 from 2 to 12 microgrammes \u2014 and induced increases in virus-neutralizing antibodies as well as the first signs of T-cell activation. T cells are a type of white blood cell that help destroy infection.<strong> <\/strong> <\/p>\n<p>Analysts and medical experts are paying close attention to these two metrics.<\/p>\n<p>The Phase 1 study has, to date, enrolled more than 250 healthy individuals aged 18 to 60 years in Germany and Belgium. CureVac intends to provide a detailed Phase\u00a01 data overview and publication in a scientific journal in the coming weeks. <\/p>\n<p>Some participants experienced side effects of headache, chills and muscle pain, with a smaller number of people reporting fever. \u201cAll reported events were transient and resolved rapidly, usually within 24 to 48 hours,\u201d CureVac said.<\/p>\n<p>CureVac went public on Nasdaq in August to accelerate the development of its vaccine. The company\u2019s stock more than <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/trip-and-travel\/\" data-internallinksmanager029f6b8e52c=\"10\" title=\"Trip &amp; Travel\" target=\"_blank\" rel=\"noopener\">trip<\/a>led in its first day of trading and is now valued at almost $9 billion.<\/p>\n<p>The company is backed by Microsoft<br \/>\n        MSFT,<br \/>\n        <bg-quote field=\"percentchange\" format=\"0,000.00%\" channel=\"\/zigman2\/quotes\/207732364\/composite\" class=\"negative\">-0.54%<\/bg-quote><br \/>\n      \u00a0founder and billionaire Bill Gates and German biotech investor Dietmar Hopp. In July, GlaxoSmithKline<br \/>\n        GSK,<br \/>\n        <bg-quote field=\"percentchange\" format=\"0,000.00%\" channel=\"\/zigman2\/quotes\/209463850\/composite\" class=\"positive\">+2.66%<\/bg-quote><br \/>\n      \u00a0bought a stake in the company, marking the latest move by a major drugmaker to boost capabilities to fight pandemics.\u00a0<\/p>\n<p><strong>Read: <\/strong>CureVac and EU in advanced talks for 225 million COVID-19 vaccine doses <\/p>\n<p>In August, CureVac said it was in advanced talks for the supply of at least 225 million doses of a potential COVID-19 vaccine to European Union member states.<\/p><\/div>\n<\/div><\/div>\n<p><\/p>\n<div class=\"byline article__byline\">\n<p>      <span>By<\/span><\/p>\n<div class=\"author  hasMenu\" data-scrim='{\"type\":\"author\",\"header\":\"Lina Saigol\",\"subhead\":\"The Wall Street Journal\",\"list\":[]}' itemscope itemprop=\"author\" itemtype=\"http:\/\/schema.org\/Person\">\n<h4 itemprop=\"name\"><span class=\"ez-toc-section\" id=\"Lina_Saigol\"><\/span>Lina Saigol<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/p><\/div>\n<\/div>\n<blockquote>\n<p style=\"text-align: center;\">For forums sites go to <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/forum.buradabiliyorum.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Forum.BuradaBiliyorum.Com<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\"><strong>If you want to read more <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/news\/\" data-internallinksmanager029f6b8e52c=\"2\" title=\"News\" target=\"_blank\" rel=\"noopener\">News<\/a> articles, you can visit our <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/en.buradabiliyorum.com\/news\/\" target=\"_blank\" rel=\"noopener noreferrer\">News category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n<p><span style=\"color: black;\"><a style=\"color: #ff9900;\" href=\"http:\/\/www.marketwatch.com\/news\/story.asp?guid=%7B21004575-02D4-D4B5-4572-DCFC446A519C%7D&#038;siteid=rss&#038;rss=1\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;# CureVac\u2019s COVID-19 vaccine shows immune response in Phase 1 trial &#8221; The biotech firm is using the so-called messenger RNA (mRNA) approach to develop a vaccine CureVac said it is on track to launch the final stage of testing, after its COVID-19 vaccine triggered an immune response in the Phase 1 trial. thomas kienzle\/Agence&#8230;<\/p>\n","protected":false},"author":1,"featured_media":103268,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[70897],"tags":[],"class_list":["post-103267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/103267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=103267"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/103267\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/103268"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=103267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=103267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=103267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}